COVID-19: Odisha to commence Third Phase Human Trial of Covaxin

As per reports, the third phase human trial of indigenously developed COVID-19 vaccine ‘Covaxin’ is set to commence at the Institute of Medical Sciences (IMS) and SUM Hospital in Odisha.

The hospital has been included in the list of 21 medical institutes selected by the Indian Council for Medical Research (ICMR) where the third phase trial would be conducted. Notably, it is the only medical facility in Odisha to have been selected for the trial.

Dr E Venkata Rao, Principal Investigator in the Covaxin human trial and Professor at IMS and SUM Hospital confirmed that the vaccine being developed by ICMR and Bharat Biotech has received the approval of the Central Drugs Standard Control Organisation (CDSCO) for initiating the third phase trial.

“After completion of the first and second phase of the trial with demonstrable safety profile and immunogenicity, the large scale efficacy trial involving thousands of volunteers has been planned now,” Dr Rao added.

“The age limit and eligibility/screening criteria would be relaxed and several volunteers who are otherwise apparently healthy would be recruited for the trial. Like the previous phases, half of the volunteers would receive a placebo and the remaining half would be administered Covaxin in this phase. Even healthcare workers would be recruited for the trial. The volunteers would be followed up over a considerable period of time to look at the efficacy of the vaccine in preventing the development of the coronavirus disease,” he said.

Dr Rao added that a large number of people have come forward with great enthusiasm to volunteer for the trial.

“The interested volunteers for the project could enroll themselves for the trial by registering online at under the section register for clinical trials,” he said.

Leave a comment